文献速递耳科与耳神经

双模式刺激与单侧及双侧人工耳蜗植入在双侧重度至极重度耳聋成人中的成本效益比较

The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
PubMed 文献 · Ear Hear · 2019-01-01

本研究从英国和美国公共医疗体系角度,采用成本-效用分析比较双模式刺激(人工耳蜗+助听器)与单侧及双侧人工耳蜗植入。双模式刺激在英国和美国决策确定性分别为72%和67%,是最具成本效益的方案;双侧人工耳蜗虽产生更多QALY但因费用过高而不具成本效益。

要点

  • 双模式刺激在英国和美国决策确定性分别为72%和67%,为最具成本效益方案。
  • 与单侧人工耳蜗相比,双模式刺激每人多花费174英镑(美国937美元),多获得0.114 QALY。
  • 双侧人工耳蜗虽产生更多QALY,但因费用过高而不具成本效益。

核心结论

  • 双模式刺激在英国和美国公共医疗体系视角下,在广泛的支付意愿阈值范围内均比单侧和双侧人工耳蜗植入更具成本效益。

研究设计与样本

  • 成本-效用分析,采用英国和美国公共医疗体系视角,基于Markov状态转移模型估算终身成本和健康效益,效用基于健康效用指数(HUI)估算,健康结局以质量调整生命年(QALY)表示。
  • 比较双模式刺激(人工耳蜗+助听器)与单侧人工耳蜗、双侧人工耳蜗两种替代方案。
  • 采用增量成本效果比(ICER)和净货币效益法评估成本效益,并进行了概率敏感性分析(蒙特卡洛模拟)、确定性敏感性分析、协方差分析及信息价值分析。

主要发现

  • 基础案例模型显示双模式刺激在英国和美国的决策确定性分别为72%和67%。
  • 双侧人工耳蜗虽比单侧人工耳蜗和双模式刺激产生更多QALY,但因费用过高而不具成本效益。
  • 与单侧人工耳蜗相比,双模式刺激在英国每人多花费174英镑(美国937美元),多获得0.114 QALY。
  • 双模式刺激与单侧人工耳蜗相比,增量成本效果比在英国为每获得1个QALY需1521英镑(美国为8192美元/QALY)。
  • 对模型影响最大的变量是同时使用两种设备(人工耳蜗+助听器)相较于单侧人工耳蜗所获得的效用。

局限性

  • 作者认为,若未来有条件开展研究,采用干预性设计获取双模式刺激相较于单侧人工耳蜗的效用值,将大幅降低决策不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: An increasing number of severe-profoundly deaf adult unilateral cochlear implant (CI) users receive bimodal stimulation; that is, they use a conventional acoustic hearing aid (HA) in their nonimplanted ear. The combination of electric and contralateral acoustic hearing provides additional benefits to hearing and also to general health-related quality of life compared with unilateral CI use. Bilateral CI is a treatment alternative to both unilateral CI and bimodal stimulation in some healthcare systems. The objective of this study was to conduct an economic evaluation of bimodal stimulation compared with other management options for adults with bilateral severe to profound deafness. DESIGN: The economic evaluation took the form of a cost-utility analysis and compared bimodal stimulation (CI+HA) to two treatment alternatives: unilateral and bilateral CI. The analysis used a public healthcare system perspective based on data from the United Kingdom and the United States. Costs and health benefits were identified for both alternatives and estimated across a patient's lifetime using Markov state transition models. Utilities were based on Health Utilities Index estimates, and health outcomes were expressed in Quality Adjusted Life Years (QALYs). The results were presented using the Incremental Cost-Effectiveness Ratio and the Net Monetary Benefit approach to determine the cost-effectiveness of bimodal stimulation. Probabilistic sensitivity analyses explored the degree of overall uncertainty using Monte Carlo simulation. Deterministic sensitivity analyses and analysis of covariance identified parameters to which the model was most sensitive; that is, whose values had a strong influence on the intervention that was determined to be most cost-effective. A value of information analysis was performed to determine the potential value to be gained from additional research on bimodal stimulation. RESULTS: The base case model showed that bimodal stimulation was the most cost-effective treatment option with a decision certainty of 72 and 67% in the United Kingdom and United States, respectively. Despite producing more QALYs than either unilateral CI or bimodal stimulation, bilateral CI was found not to be cost-effective because it was associated with excessive costs. Compared with unilateral CI, the increased costs of bimodal stimulation were outweighed by the gain in quality of life. Bimodal stimulation was found to cost an extra £174 per person in the United Kingdom ($937 in the US) and yielded an additional 0.114 QALYs compared with unilateral CI, resulting in an Incremental Cost-Effectiveness Ratio of £1521 per QALY gained in the United Kingdom ($8192/QALY in the United States). The most influential variable was the utility gained from the simultaneous use of both devices (CI+HA) compared with Unilateral CI. The value of further research was £4,383,922 at £20,000/QALY ($86,955,460 at $50,000/QALY in the United States). CONCLUSIONS: This study provides evidence of the most cost-effective treatment alternative for adults with bilateral severe to profound deafness from publicly funded healthcare perspectives of the United Kingdom and United States. Bimodal stimulation was found to be more cost-effective than unilateral and bilateral CI across a wide range of willingness-to-pay thresholds. If there is scope for future research, conducting interventional designs to obtain utilities for bimodal stimulation compared with unilateral CI would reduce decision uncertainty considerably.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Theriou C, Fielden CA, Kitterick PT, et al. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness. Ear Hear. 2019. PMID: 30998548. doi:10.1097/AUD.0000000000000727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。